Tag: MRK

Finance

Healthcare Active Movers: Geron Corporation (NASDAQ:GERN), Merck (NYSE:MRK), Valeant Pharmaceuticals (NYSE:VRX), Johnson & Johnson (NYSE:JNJ), Novavax (NASDAQ:NVAX)

Geron Corporation (NASDAQ:GERN) was one of the Nasdaq’s most active movers, jumping 23 per cent to $3.20 on heavy volume after the US Food and Drug Administration lifted a partial clinical hold on a study testing its blood cancer drug. Geron Corporation (NASDAQ:GERN) stock performance was 21.15% in last session and finished the day at $3.15. Traded volume was 47.60million shares in the last session … Continue reading Healthcare Active Movers: Geron Corporation (NASDAQ:GERN), Merck (NYSE:MRK), Valeant Pharmaceuticals (NYSE:VRX), Johnson & Johnson (NYSE:JNJ), Novavax (NASDAQ:NVAX)

Jayne Crisman
Finance

Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Zogenix, Inc (NASDAQ:ZGNX) CEO Roger Hawley unloaded 25,078 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.10, for a total transaction of $52,663.80. Following the completion of the sale, the chief executive officer now directly owns 1,204,447 shares in the company, valued at approximately $2,529,339. Zogenix, … Continue reading Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Richard Atkins
Finance

Notable Movers: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Bayer AG (ADR) (OTCMKTS:BAYRY)

Pfizer Inc (NYSE:PFE) Insider Geno J. Germano unloaded 30,000 shares of the stock on the open market in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $29.68, for a total value of $890,400.00. Following the transaction, the insider now directly owns 263,495 shares of the company’s stock, valued at approximately $7,820,532. Pfizer Inc. (NYSE:PFE) stock performance … Continue reading Notable Movers: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Bayer AG (ADR) (OTCMKTS:BAYRY)

Jason Knox
Finance

Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE)’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses, but promised to keep key research jobs in Britain as part of its $106 billion takeover bid. Pfizer Inc. (NYSE:PFE) stock performance was 0.24% in last session and finished the day at $29.20. Traded volume was 26.29million shares in the last session and the average volume of … Continue reading Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis
Finance

Hot Stocks: National Bank of Greece (NYSE:NBG), Exxon Mobil Corporation (NYSE:XOM), Merck & Co. (NYSE:MRK), Hewlett-Packard Company (NYSE:HPQ)

As the European Central Bank prepares to take over supervision of about 130 euro-area lenders from BNP Paribas to National Bank of Greece (ADR) (NYSE:NBG) starting in November, regulators have sought to compile the toughest stress tests in a bid to repair credibility damaged by assessments in 2010 and 2011 that didn’t uncover weaknesses at banks that later failed. National Bank of Greece (ADR) (NYSE:NBG) … Continue reading Hot Stocks: National Bank of Greece (NYSE:NBG), Exxon Mobil Corporation (NYSE:XOM), Merck & Co. (NYSE:MRK), Hewlett-Packard Company (NYSE:HPQ)

Colin Pettis
Finance

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million … Continue reading Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis1 Comment